AlphAIAlphAI — Financial news for AI agents
sci-tech-today.comAUG 104 min read$LFMD

LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate

LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3M, below the $49.16M consensus estimate, with GAAP EPS loss of $0.16 versus a $0.01 EPS expectation. The company posted an adjusted EBITDA loss and cut full-year 2026 guidance to $205.5M–$212.5M revenue and negative $6M to breakeven adjusted EBITDA. LFMD shares fell after the release.

Original reporting
sci-tech-today.com
Published Aug 10, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 12:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
LifeMD Q2 2026 Earnings: Revenue Misses $49.16M Estimate — source image
Source · sci-tech-today.com
Decision brief

The 30-second read

$LFMDBearishHigh
01

Why it matters

The quarter combined a revenue/EPS miss with a larger-than-expected reduction in full-year 2026 revenue and adjusted EBITDA range, prompting a sharp after-hours decline.

02

Market read

Traders are likely to focus on the guidance cut and the path to adjusted EBITDA breakeven, not just gross margin and subscriber growth.

03

What to watch

The article notes the transition away from compounded GLP-1s is near completion (95% of new Weight Management patients on branded GLP-1s), which may improve longer-term unit economics despite the near-term guidance reset.

Relevance 9/10Novelty 8/10Timing: after-hours reaction on Aug 10, 2026 earnings release

Background

LifeMD is shifting its revenue mix toward recurring subscriptions and branded GLP-1 therapies, with an in-house pharmacy and telehealth plus affiliated medical group.

Company-level read

Ticker impact

$LFMDBearishHigh confidence
Context

LifeMD reported Q2 2026 revenue of $47.3M and GAAP EPS loss of $0.16, missing consensus and cutting full-year 2026 guidance.

Expected impact

Bearish near-term bias; elevated volatility likely as traders digest the guidance reset and subscriber mix shift to branded GLP-1s.

Evidence & confidence

The article cites both the miss (revenue and EPS) and a material guidance reduction for 2026, alongside a 12.23% after-hours drop.

Market effects

Sector

Signals pressure on virtual-care profitability and the earnings sensitivity of GLP-1 transition economics for subscription-based telehealth models.

Regional

Primarily impacts US small-cap healthcare/telehealth sentiment; limited direct cross-region spillover implied.

Global

Low global relevance beyond the US virtual-care and GLP-1-adjacent investor cohort.

Counterpoint

What could challenge this read

Gross margin expanded to ~89% and subscribers rose to ~356,000, suggesting operating leverage could re-emerge if acquisition spending normalizes.

Key entities

  • company
    LifeMD, Inc.

    Nasdaq-listed virtual-care provider reporting Q2 2026 results and reduced 2026 guidance.

  • executive
    Justin Schreiber

    Chairman and CEO quoted on longer patient relationships and diversified acquisition model.

  • executive
    Atul Kavthekar

    CFO quoted on gross margin expansion drivers and pharmacy scaling.

Read at source← All news

Related articles

SEP 16
$TMed

AT&T Waives $19 LifeMD Fee for 100 Million Wireless and Fiber Customers

AT&T is partnering with LifeMD to waive its $19 monthly membership fee for over 100 million wireless and fiber customers, making it the first carrier to bundle no-cost virtual healthcare access. The rollout begins in 11 states, with the rest following in January 2027. LifeMD (LFMD) provides telehealth services, and AT&T aims to enhance customer retention. AT&T's stock is valued at $29.03 per share, with projected slight earnings declines due to heavy capital spending.

kobaran.com3 min
AUG 13
$LFMDMedAI 9/10

LifeMD (LFMD) Q2 2026 Earnings Call Transcript

LifeMD (LFMD) reported Q2 2026 revenue of $47.3M, within guidance ($47M-$50M) but down 4% YoY, and an adjusted EBITDA loss of about $3.5M. Full-year revenue guidance was cut to $205.5M-$212.5M and adjusted EBITDA to negative $6M to breakeven. Active subscribers were 356,000. Cash was $25.1M.

fool.com6 min
AUG 5
$LFMDMed

LifeMD, Inc. (LFMD): Results of Operations and Financial Condition

LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. ● Approximately

SEC EDGAR 8-K6 min
SEP 17
$TSLAHighAI 9/10

Tesla Posted Negative $1.1 Billion in Free Cash Flow Last Quarter as Elon Musk Ramps Up Spending on Robotaxis and Optimus. Here's Why the Company's $43.5 Billion Cash Cushion Still Matters.

Tesla reported a 26% revenue increase to $22.5B in Q2, with net income of $1.11B, but negative free cash flow of $1.1B due to $5.79B in capital expenditures. The company's $43.5B cash position provides a buffer for growth investments in robotaxis, Optimus robots, and semiconductors. Tesla's market share in U.S. EVs has risen despite industry contraction, but competition from Chinese rivals like BYD persists.

fool.com2 min
SEP 17
$BWINMed

Michael Dell Just Made a $7.7 Billion Bet on This Insurance Stock

Michael Dell is acquiring Baldwin & Co. (BWIN) for $7.7B. Baldwin reported Q2 revenue of $492.9M (+30% YoY), adjusted net income of $68.5M, and adjusted EBITDA of $116.7M (+37%). Management guided Q3 revenue to $485M-$495M and full-year revenue to $2.01B-$2.05B. Analysts have mixed targets, with a consensus 'Moderate Buy' and average target of $33.

yahoo.com2 min